AINMF (NetraMark Holdings) 3-Year RORE % : -46.48% (As of Mar. 2026)


AINMF NetraMark Holdings Inc AINMF
31 GF Score
Price $0.56
GF Value $0.21
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is NetraMark Holdings 3-Year RORE %?

NetraMark Holdings AINMF 31 3-Year RORE % is -46.48 as of Mar. 2026. GuruFocus rates AINMF with a GF Score™ of 31/100 and a GF Value™ of $0.21 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 605 Healthcare Providers & Services companies, NetraMark Holdings ranks worse than 80% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. NetraMark Holdings's 3-Year RORE % for the quarter that ended in Mar. 2026 was -46.48%.

The industry rank for NetraMark Holdings's 3-Year RORE % or its related term are showing as below:

AINMF's 3-Year RORE % is ranked worse than
80% of 605 companies
in the Healthcare Providers & Services industry
Industry Median: -0.32 vs AINMF: -46.48

NetraMark Holdings  (OTCPK:AINMF) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


NetraMark Holdings 3-Year RORE % Related Terms


NetraMark Holdings 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for NetraMark Holdings's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NetraMark Holdings 3-Year RORE % Chart

NetraMark Holdings Annual Data
Trend Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
3-Year RORE %
Get a 7-Day Free Trial 0.00 0.00 10.34 -45.36 -56.31

NetraMark Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -42.17 -43.72 -56.31 -51.33 -46.48

AINMF vs VEEV, BTSG, TEM: 3-Year RORE % Comparison

For the Health Information Services subindustry, NetraMark Holdings's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NetraMark Holdings 3-Year RORE % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, NetraMark Holdings's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where NetraMark Holdings's 3-Year RORE % falls into.


AINMF
31GF Score
NetraMark Holdings Inc AINMF
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NetraMark Holdings 3-Year RORE % Calculation

NetraMark Holdings's 3-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.051--0.17 )/( -0.256-0 )
=0.119/-0.256
=-46.48 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -46.48 mean?
NetraMark Holdings (AINMF) has a 3-Year RORE % of -46.48 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on NetraMark Holdings and its competitors. According to the industry distribution chart, NetraMark Holdings ranks #484 out of 605 companies in the Healthcare Providers & Services industry, placing it in the top 80%.
Is NetraMark Holdings' 3-Year RORE % too high?
NetraMark Holdings' current 3-Year RORE % is -46.48. Based on the distribution chart, NetraMark Holdings ranks #484 out of 605 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, NetraMark Holdings has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NetraMark Holdings' 3-Year RORE % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, NetraMark Holdings ranks #484 out of 605 companies for 3-Year RORE %. This places NetraMark Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Healthcare Providers & Services company?
A good 3-Year RORE % depends on the Healthcare Providers & Services industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on NetraMark Holdings and its competitors. NetraMark Holdings's current 3-Year RORE % is -46.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NetraMark Holdings stock overvalued right now?
Based on GuruFocus' analysis, NetraMark Holdings (AINMF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.21, compared to a current price of $0.56 — trading 167.4% above its estimated fair value. The current 3-Year RORE % is -46.48. NetraMark Holdings' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For NetraMark Holdings (AINMF), the current 3-Year RORE % is -46.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NetraMark Holdings (AINMF) Overvalued in 2026?

Based on GuruFocus' analysis, NetraMark Holdings stock appears to be overvalued. The current stock price of $0.56 is trading 167.4% above its estimated GF Value™ of $0.21. GuruFocus considers NetraMark Holdings to be Significantly Overvalued.

Key valuation signals for AINMF:

  • 3-Year RORE %: -46.48
  • GF Value™: $0.21 vs. price of $0.56 (167.4% above fair value)
  • GF Score™: 31/100 with 2 warning signs

No single metric tells the full story. See the AINMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


NetraMark Holdings Business Description

Other Exchanges PF0:GermanyAIAI:Canada
Address 1655 Dupont Street, Suite 101, Toronto, ON, CAN, M6P 3T1
NetraMark Holdings Inc provides AI-powered insights and software solutions to optimize clinical trial design and outcomes for pharmaceutical sponsors. The company offers AI solutions to trial sponsors, CROs, and biotechnology companies across the globe. It earns revenue from its proprietary NetraAI platform, an advanced machine learning system purpose-built to analyze complex clinical trial data and identify meaningful patient subpopulations.
31GF Score

Get the complete analysis for AINMF

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.56
Price
$0.21
GF Value